{"id":33516,"date":"2025-06-02T13:02:25","date_gmt":"2025-06-02T11:02:25","guid":{"rendered":"https:\/\/dupmecp2.eu\/?p=33516"},"modified":"2025-09-10T13:19:47","modified_gmt":"2025-09-10T11:19:47","slug":"umass-chan-licences-sirna-technology","status":"publish","type":"post","link":"https:\/\/dupmecp2.eu\/en\/umass-chan-licences-sirna-technology\/","title":{"rendered":"A new step forward in the search for a cure: UMass Chan licenses siRNA technology \u00a0"},"content":{"rendered":"<p>UMass Chan Medical School has licensed a promising siRNA-based technology to M2DS, a startup company dedicated to advancing the technology as a treatment for MECP2 Duplication Syndrome. This marks a major step forward in translating cutting-edge research into clinical reality.&nbsp;<\/p>\n\n\n\n<p>The technology was developed in the lab of Dr. Khvorova, with the project led by Vignesh Hariharan. Early research was made thanks to funding from Cure MDS and the Rett Syndrome Research Trust. This siRNA works by targeting and degrading the messenger RNA responsible for the overproduction of the MeCP2 protein.&nbsp;<\/p>\n\n\n\n<p>In mice studies, a dose reached the brain and spinal cord effectively and may only require once- or twice-yearly administration. By licensing this technology to M2DS, the therapy now enters a pathway where it can receive the support needed to advance toward human trials.&nbsp;&nbsp;<\/p>\n\n\n\n<p>In addition to ongoing clinical trials from Ionis and HuidaGene, this milestone may add a promising addition to the pipeline of potential treatments for this rare and complex disorder.&nbsp;<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link has-white-color has-text-color has-background has-link-color wp-element-button\" href=\"https:\/\/bridge.umassmed.edu\/s\/news\/news-article\/umass-chan-licenses-sirna-therapeutics-for-mecp2-duplication-syndrome-MCMWKNCJYQ25CQHF5YITTOM757HU\" style=\"border-radius:11px;background-color:#f7a13f\">Press Release<\/a><\/div>\n<\/div>\n\n\n\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>L&rsquo;\u00e9cole de m\u00e9decine UMass Chan a octroy\u00e9 une licence pour une technologie prometteuse bas\u00e9e sur le siRNA \u00e0 M2DS, une start-up visant \u00e0 faire progresser cette technologie en tant que [&hellip;]<\/p>","protected":false},"author":1,"featured_media":33517,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-33516","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualite"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Une nouvelle avanc\u00e9e dans la recherche d&#039;un traitement : l&#039;UMass Chan octroie une licence pour la technologie siRNA \u00a0 - DupMECP2<\/title>\n<meta name=\"description\" content=\"L&#039;\u00e9cole de m\u00e9decine UMass Chan a octroy\u00e9 une licence pour une technologie prometteuse bas\u00e9e sur le siRNA \u00e0 M2DS, une start-up visant \u00e0 faire progresser cette technologie en tant que traitement du syndrome de duplication du g\u00e8ne MECP2. Cela marque une avanc\u00e9e majeure dans la poursuite vers une application clinique.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dupmecp2.eu\/en\/umass-chan-licences-sirna-technology\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Une nouvelle avanc\u00e9e dans la recherche d&#039;un traitement : l&#039;UMass Chan octroie une licence pour la technologie siRNA \u00a0 - DupMECP2\" \/>\n<meta property=\"og:description\" content=\"L&#039;\u00e9cole de m\u00e9decine UMass Chan a octroy\u00e9 une licence pour une technologie prometteuse bas\u00e9e sur le siRNA \u00e0 M2DS, une start-up visant \u00e0 faire progresser cette technologie en tant que traitement du syndrome de duplication du g\u00e8ne MECP2. Cela marque une avanc\u00e9e majeure dans la poursuite vers une application clinique.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dupmecp2.eu\/en\/umass-chan-licences-sirna-technology\/\" \/>\n<meta property=\"og:site_name\" content=\"DupMECP2\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-02T11:02:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-10T11:19:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Caroline\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/\"},\"author\":{\"name\":\"Caroline\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\"},\"headline\":\"Une nouvelle avanc\u00e9e dans la recherche d&rsquo;un traitement : l&rsquo;UMass Chan octroie une licence pour la technologie siRNA \u00a0\",\"datePublished\":\"2025-06-02T11:02:25+00:00\",\"dateModified\":\"2025-09-10T11:19:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/\"},\"wordCount\":245,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg\",\"articleSection\":[\"Actualit\u00e9\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/\",\"url\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/\",\"name\":\"Une nouvelle avanc\u00e9e dans la recherche d'un traitement : l'UMass Chan octroie une licence pour la technologie siRNA \u00a0 - DupMECP2\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg\",\"datePublished\":\"2025-06-02T11:02:25+00:00\",\"dateModified\":\"2025-09-10T11:19:47+00:00\",\"description\":\"L'\u00e9cole de m\u00e9decine UMass Chan a octroy\u00e9 une licence pour une technologie prometteuse bas\u00e9e sur le siRNA \u00e0 M2DS, une start-up visant \u00e0 faire progresser cette technologie en tant que traitement du syndrome de duplication du g\u00e8ne MECP2. Cela marque une avanc\u00e9e majeure dans la poursuite vers une application clinique.\",\"breadcrumb\":{\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#primaryimage\",\"url\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg\",\"contentUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg\",\"width\":1080,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/dupmecp2.eu\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Actualit\u00e9\",\"item\":\"https:\/\/dupmecp2.eu\/category\/actualite\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Une nouvelle avanc\u00e9e dans la recherche d&#8217;un traitement : l&#8217;UMass Chan octroie une licence pour la technologie siRNA \u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dupmecp2.eu\/#website\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"name\":\"DupMECP2\",\"description\":\"EU\",\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dupmecp2.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dupmecp2.eu\/#organization\",\"name\":\"DupMECP2\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"DupMECP2\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\",\"name\":\"Caroline\",\"sameAs\":[\"https:\/\/dupmecp2.eu\"],\"url\":\"https:\/\/dupmecp2.eu\/en\/author\/417a2385dc37aa45\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"A new breakthrough in the search for a treatment: UMass Chan licenses siRNA technology - DupMECP2","description":"The UMass Chan School of Medicine has licensed a promising siRNA-based technology to M2DS, a start-up aimed at advancing this technology as a treatment for MECP2 gene duplication syndrome. This marks a major step forward in the pursuit of clinical application.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dupmecp2.eu\/en\/umass-chan-licences-sirna-technology\/","og_locale":"en_GB","og_type":"article","og_title":"Une nouvelle avanc\u00e9e dans la recherche d'un traitement : l'UMass Chan octroie une licence pour la technologie siRNA \u00a0 - DupMECP2","og_description":"L'\u00e9cole de m\u00e9decine UMass Chan a octroy\u00e9 une licence pour une technologie prometteuse bas\u00e9e sur le siRNA \u00e0 M2DS, une start-up visant \u00e0 faire progresser cette technologie en tant que traitement du syndrome de duplication du g\u00e8ne MECP2. Cela marque une avanc\u00e9e majeure dans la poursuite vers une application clinique.","og_url":"https:\/\/dupmecp2.eu\/en\/umass-chan-licences-sirna-technology\/","og_site_name":"DupMECP2","article_published_time":"2025-06-02T11:02:25+00:00","article_modified_time":"2025-09-10T11:19:47+00:00","og_image":[{"width":1080,"height":1080,"url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg","type":"image\/jpeg"}],"author":"Caroline","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Caroline","Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#article","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/"},"author":{"name":"Caroline","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee"},"headline":"Une nouvelle avanc\u00e9e dans la recherche d&rsquo;un traitement : l&rsquo;UMass Chan octroie une licence pour la technologie siRNA \u00a0","datePublished":"2025-06-02T11:02:25+00:00","dateModified":"2025-09-10T11:19:47+00:00","mainEntityOfPage":{"@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/"},"wordCount":245,"commentCount":0,"publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"image":{"@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg","articleSection":["Actualit\u00e9"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/","url":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/","name":"A new breakthrough in the search for a treatment: UMass Chan licenses siRNA technology - DupMECP2","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#primaryimage"},"image":{"@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg","datePublished":"2025-06-02T11:02:25+00:00","dateModified":"2025-09-10T11:19:47+00:00","description":"The UMass Chan School of Medicine has licensed a promising siRNA-based technology to M2DS, a start-up aimed at advancing this technology as a treatment for MECP2 gene duplication syndrome. This marks a major step forward in the pursuit of clinical application.","breadcrumb":{"@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#primaryimage","url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg","contentUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg","width":1080,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/dupmecp2.eu\/"},{"@type":"ListItem","position":2,"name":"Actualit\u00e9","item":"https:\/\/dupmecp2.eu\/category\/actualite\/"},{"@type":"ListItem","position":3,"name":"Une nouvelle avanc\u00e9e dans la recherche d&#8217;un traitement : l&#8217;UMass Chan octroie une licence pour la technologie siRNA \u00a0"}]},{"@type":"WebSite","@id":"https:\/\/dupmecp2.eu\/#website","url":"https:\/\/dupmecp2.eu\/","name":"DupMECP2","description":"EU","publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dupmecp2.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/dupmecp2.eu\/#organization","name":"DupMECP2","url":"https:\/\/dupmecp2.eu\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"DupMECP2"},"image":{"@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee","name":"Caroline","sameAs":["https:\/\/dupmecp2.eu"],"url":"https:\/\/dupmecp2.eu\/en\/author\/417a2385dc37aa45\/"}]}},"_links":{"self":[{"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/posts\/33516","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/comments?post=33516"}],"version-history":[{"count":2,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/posts\/33516\/revisions"}],"predecessor-version":[{"id":33521,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/posts\/33516\/revisions\/33521"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/media\/33517"}],"wp:attachment":[{"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/media?parent=33516"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/categories?post=33516"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dupmecp2.eu\/en\/wp-json\/wp\/v2\/tags?post=33516"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}